GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Down 51.2% in March

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 1,019,371 shares, a decline of 51.2% from the February 26th total of 2,089,377 shares. Based on an average daily trading volume, of 729,020 shares, the days-to-cover ratio is presently 1.4 days. Currently, 3.3% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of GT Biopharma in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new stake in GT Biopharma, Inc. (NASDAQ:GTBP) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned approximately 0.47% of GT Biopharma as of its most recent filing with the SEC. Institutional investors own 8.15% of the company’s stock.

GT Biopharma Price Performance

GTBP traded down $0.02 during trading on Thursday, reaching $0.45. 404,814 shares of the stock traded hands, compared to its average volume of 1,215,240. The stock’s 50-day simple moving average is $0.52 and its two-hundred day simple moving average is $0.66. GT Biopharma has a fifty-two week low of $0.39 and a fifty-two week high of $3.85. The stock has a market cap of $14.07 million, a price-to-earnings ratio of -0.07 and a beta of 1.28.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).